Literature DB >> 15563545

Induction and regulation of Fas-mediated apoptosis in human thyroid epithelial cells.

Emese Mezosi1, Su He Wang, Saho Utsugi, Laszlo Bajnok, James D Bretz, Paul G Gauger, Norman W Thompson, James R Baker.   

Abstract

Fas-mediated apoptosis has been proposed to play an important role in the pathogenesis of Hashimoto's thyroiditis. Normal thyroid cells are resistant to Fas-mediated apoptosis in vitro but can be sensitized by the unique combination of interferon-gamma and IL-1beta cytokines. We sought to examine the mechanism of this sensitization and apoptosis signaling in primary human thyroid cells. Without the addition of cytokines, agonist anti-Fas antibody treatment of the thyroid cells resulted in the cleavage of proximal caspases, but this did not lead to the activation of caspase 7 and caspase 3. Apoptosis associated with the cleavage of caspases 7, 3, and Bid, and the activation of mitochondria in response to anti-Fas antibody occurred only after cytokine pretreatment. Cell surface expression of Fas, the cytoplasmic concentrations of procaspases 7, 8, and 10, and the proapoptotic molecule Bid were markedly enhanced by the presence of the cytokines. In contrast, P44/p42 MAPK (Erk) appeared to provide protection from Fas-mediated apoptosis because an MAPK kinase inhibitor (U0126) sensitized thyroid cells to anti-Fas antibody. In conclusion, Fas signaling is blocked in normal thyroid cells at a point after the activation of proximal caspases. Interferon-gamma/IL-1beta pretreatment sensitizes human thyroid cells to Fas-mediated apoptosis in a complex manner that overcomes this blockade through increased expression of cell surface Fas receptor, increases in proapoptotic molecules that result in mitochondrial activation, and late caspase cleavage. This process involves Bcl-2 family proteins and appears to be compatible with type II apoptosis regulation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15563545     DOI: 10.1210/me.2004-0286

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  7 in total

1.  Endocrine disruption as an adverse effect of non-endocrine targeting pharmaceuticals.

Authors:  Shakila Sabir; Muhammad Furqan Akhtar; Ammara Saleem
Journal:  Environ Sci Pollut Res Int       Date:  2018-11-22       Impact factor: 4.223

2.  Autoimmune hypothyroidism is three times more frequent in female prolactinoma patients compared to healthy women: data from a cross-sectional case-control study.

Authors:  Atanaska Elenkova; Iliana Аtanasova; Georgi Кirilov; Еmil Natchev; Ralitza Ivanova; Roussanka Кovatcheva; Silvia Vandeva; Dimitar Tcharaktchiev; Sabina Zacharieva
Journal:  Endocrine       Date:  2017-07-19       Impact factor: 3.633

3.  Cultured murine thyroid epithelial cells expressing transgenic Fas-associated death domain-like interleukin-1beta converting enzyme inhibitory protein are protected from fas-mediated apoptosis.

Authors:  Yujiang Fang; Helen Braley-Mullen
Journal:  Endocrinology       Date:  2008-03-20       Impact factor: 4.736

4.  Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4+CD25+ regulatory T cells.

Authors:  Su He Wang; Gwo-Hsiao Chen; Yongyi Fan; Mary Van Antwerp; James R Baker
Journal:  Endocrinology       Date:  2008-11-13       Impact factor: 4.736

5.  Overexpression of BID in thyroids of transgenic mice increases sensitivity to iodine-induced autoimmune thyroiditis.

Authors:  Su He Wang; Yongyi Fan; James R Baker
Journal:  J Transl Med       Date:  2014-06-23       Impact factor: 5.531

Review 6.  The Roles of Exosomes in Immunoregulation and Autoimmune Thyroid Diseases.

Authors:  Junli Zou; Huiyong Peng; Yingzhao Liu
Journal:  Front Immunol       Date:  2021-11-15       Impact factor: 7.561

7.  Death-associated protein 3 is overexpressed in human thyroid oncocytic tumours.

Authors:  C Jacques; J-F Fontaine; B Franc; D Mirebeau-Prunier; S Triau; F Savagner; Y Malthiery
Journal:  Br J Cancer       Date:  2009-06-16       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.